跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
YUFLYMA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
YUFLYMA
Authorized
STANDARD
YUFLYMA
Celltrion Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a7b228d32281d83a
Company
Celltrion Inc
Type
Standard
Approval Details
Approval Id
a7b228d32281d83a
Drug Approval Canada Name
YUFLYMA
Product Name
YUFLYMA
Status
Marketed
Status Date
2024-06-21
Original Market Date
2023-08-14
Din
02535076
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
90:24.16.92
Atc Original
L04AB04 ADALIMUMAB
Atc Name
l 04 ab 04
Aig Number
0150364002
Company Name
Celltrion Inc
Company Address
23 Academy-Ro, Yeonsu-Gu, Incheon, --, Korea, Republic Of, 22014
Company Detail Path
/organization/celltrion-inc
Company Information
Pharmaceutical Company Name
Celltrion, Inc.
Name En
Celltrion, Inc.
Name Zh
塞尔群
Country Name
South Korea
Province Name
仁川广域市
City Name
Yeonsu-gu, Incheon
Address
Yeonsu-gu, Incheon, South Korea
Website
https://www.celltrion.com
Description
South Korean biopharmaceutical company headquartered in Incheon, developing and distributing biosimilar monoclonal antibody therapies for rheumatoid arthritis, cancer, and inflammatory diseases.
Active Ingredients
ADALIMUMAB
80 MG / 0.8 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a7b228d32281d83a
Type
Standard
Back to Health Canada Approvals